Table 4B.
Demographic, clinical, cognitive, functioning profiles of two clusters.
| Variables | HC & Baseline FEPa | HC & Follow-Up FEPb | Baseline & Follow-Up FEPc | |||
|---|---|---|---|---|---|---|
| Cluster 1: higher AverageDifference (N = 29) | Cluster 2: lower AverageDifference(N = 22) | Cluster 1: higher AverageDifference(N = 24) | Cluster 2: lower AverageDifference(N = 23) | Cluster 1: higher AverageDifference(N = 10) | Cluster 2: lower AverageDifference(N = 26) | |
| Patients (count, %) |
12 (41.38%) |
8 (36.36%) |
7 (29.17%) |
9 (39.13%) |
N/A | N/A |
| Schizophrenia (count, %) |
N/A | N/A | N/A | N/A | 6 (60.00%) |
10 (38.46%) |
| Age | 22.9 (2.8) |
22.82 (2.8) |
22.92 (2.8) |
23.39 (2.8) |
23.0 (3.0) |
23.08 (3.0) |
| Females (count, %) |
7 (24.14%) |
11 (50.00%) | 6 (25.00%) |
10 (43.48%) | 2 (20.00%) |
10 (38.46%) |
| Education (years) | 15.24 (1.6) |
15.36 (1.6) |
15.12 (1.5) |
15.7 (1.5) |
14.6 (0.8) |
15.23 (0.8) |
| UPSA | 81.7 (9.0) |
82.07 (9.0) |
79.79 (12.2) | 85.47 (12.2) | 76.46 (11.9) | 82.44 (11.9) |
| MCAS | 52.3 (4.7) |
51.4 (4.7) |
52.48 (4.5) |
52.57 (4.5) |
48.89 (5.3) |
48.08 (5.3) |
| MCAS Independent Subscore | 9.55 (1.0) |
9.27 (1.0) |
9.5 (1.3) |
9.19 (1.3) |
8.38 (1.8) |
8.14 (1.8) |
| MCAS Social Subscore | 18.9 (2.3) |
18.77 (2.3) |
19.1 (1.7) |
19.33 (1.7) |
17.62 (2.5) |
17.18 (2.5) |
| MATRICS Social Subscore | 53.71 (9.7) |
54.64 (9.7) |
54.32 (9.1) |
54.05 (9.1) |
51.14 (12.9) | 54.24 (12.9) |
| MATRICS Neurocognitive Composite Score |
47.63 (6.5) |
50.22 (6.5) |
49.45 (5.7) |
50.72 (5.7) |
46.07 (5.4) |
47.79 (5.4) |
| TASIT | 53.65 (5.1) |
56.29 (5.1) |
53.67
(4.5) |
56.47
(4.5) |
52.43 (5.3) |
54.5 (5.3) |
| PANSS Positive | N/A | N/A | N/A | N/A | 12.44 (5.7) |
14.08 (5.7) |
| PANSS Negative | N/A | N/A | N/A | N/A | 10.67 (4.2) |
11.77 (4.2) |
| PANSS General | N/A | N/A | N/A | N/A | 28.11 (7.7) |
29.0 (7.7) |
| PANSS Total | N/A | N/A | N/A | N/A | 51.22 (16.7) | 54.85 (16.7) |
Note 1: means with standard deviations in parentheses unless otherwise specified. Note 2: aBaseline measures were used for both HC and FEP subjects; bBaseline measures were used for HC and follow-up measures were used for patients; cBaseline measures were used for baseline patients and follow-up measures were used for follow-up patients.